US 11,655,291 B2
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A
Trevor Stitt, Ridgewood, NJ (US); and Esther Latres, New York, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneran Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Jul. 17, 2019, as Appl. No. 16/514,858.
Application 16/514,858 is a continuation of application No. 15/893,480, filed on Feb. 9, 2018, granted, now 10,400,036.
Application 15/893,480 is a continuation of application No. 15/282,489, filed on Sep. 30, 2016, abandoned.
Application 15/282,489 is a continuation of application No. 15/077,662, filed on Mar. 22, 2016, abandoned.
Application 15/077,662 is a continuation of application No. 14/496,941, filed on Sep. 25, 2014, abandoned.
Application 14/496,941 is a continuation of application No. 13/676,233, filed on Nov. 14, 2012, granted, now 8,871,209.
Claims priority of provisional application 61/559,175, filed on Nov. 14, 2011.
Claims priority of provisional application 61/607,024, filed on Mar. 6, 2012.
Claims priority of provisional application 61/661,451, filed on Jun. 19, 2012.
Prior Publication US 2020/0010540 A1, Jan. 9, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/22 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/22 (2013.01) [A61K 39/3955 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 22 Claims
 
1. A method for treating, preventing, or ameliorating decreased muscle mass or strength in a subject having a disease or disorder characterized by decreased muscle mass or strength, the method comprising administering to the subject in need thereof a growth and differentiation factor 8 (GDF8)-specific binding protein that inhibits GDF8 and an Activin A-specific binding protein that inhibits Activin A, wherein the GDF8-specific binding protein is a human anti-GDF8 antibody that specifically binds GDF8, wherein the anti-GDF8 antibody comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 17, and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 21.